

Contents

<i>Chapter</i>	<i>Page</i>
1. EXECUTIVE SUMMARY	3
Introduction	3
The Controversy.	3
Findings	4
Innovation in the Pharmaceutical Industry	5
Trends in the Factors Affecting Pharmaceutical Innovation	5
Implications of Patent-Term Extension for Pharmaceuticals	6
The Mechanics of Patent-Term Extension	7
2. THE ISSUE IN BRIEF	11
Introduction	11
The Patent System and Pharmaceutical Innovation.	11
The Lifecycle of a Successful NCE Pharmaceutical.	12
An Overview of the Pharmaceutical Industry	16
The Issue of Equity	19
The Positions of the Parties Interested in Patent-Term Extension.	21
3. FACTORS AFFECTING INNOVATION IN THE PHARMACEUTICAL INDUSTRY	25
Decisionmaking in the Industry.	25
Trends in Pharmaceutical Innovation	26
The Knowledge Base	26
Factors Affecting Returns to Research Investment	27
Trends in Revenues and Profits	28
The Costs of Research and Development.	33
Summary of Findings	35
4. THE IMPLICATIONS OF PATENT-TERM EXTENSION FOR PHARMACEUTICALS	39
Patent-Term Extension and Innovation	39
Patent-Term Extension and the Cost of Pharmaceuticals	41
Implications of Patent-Term Extension for Society	43
Summary of Findings	45
5. THE FUNDAMENTALS OF THE PATENT SYSTEM	49
Introduction	49
The Role of Patents in Pharmaceutical Innovation.	49
A History of U.S. Patent Law	50
The Pharmaceutical Patent	50
Securing a Patent.	53
Foreign Patents	55
6. THE MECHANICS OF PATENT-TERM EXTENSION	59
Introduction	59
Limitations in Scope and Enforcement.	59
Limitations in Remedies.	64
The Duration of Extension.	64
Other Considerations	66
Appendix: PATENT-TERM EXTENSION FOR OTHER INDUSTRIES	71
The Medical Devices Industry	71

The Pesticide Industry ..	73
The Chemical Industry ..	74

LIST OF TABLES

<i>Table No.</i>	<i>Page</i>
1. After-Tax Rates of Return on Average Stockholders' Equity 1956-79	16
2. Sales Ranking of the Top U.S. Pharmaceuticals in 1980	18
3. Percentage of Corporate Pharmaceutical Sales Accounted for by Three Leading Products	27
4. Sales of Pharmaceutical Products of U.S. Based Firms 1965-78.	28
5. Research and Development Expenditures and Sales Revenues of U.S. Ethical Drug Industry.	28
6. Producer Price Indexes for Selected Years	29
7. Average Percentage Change in Producer's Prices by Therapeutic Category, 1969-79 .	29
8. Top Selling Drugs by Volume in 1980 and Year of NDA Approval	30
9. Effective Patent Lives of 1980 Top Sellers by Revenues.	31
10. Number of Firms Receiving FDA Approval and Number of Drugs Approved, by FDA Drug Category	31
11. Average and Median Number of Years Between IND Filing and NDA Approval for NCEs	34
12. Trends in R&D Expenditures	34
13. Relative Funding of Basic and Applied Research in the Pharmaceutical Industry .	35
14. Percentage of R&D Funds Spent by Therapeutic Class	35
15. Sensitivity of the Consumer Cost of Patent-Term Extension to Three Variables .	43
16. Activities Permitted Before and After Patent Expiration.	52
A-1. New Pesticide Chemicals Registered in the United States, 1967-79.....	73
A-2. U.S. Pesticide Sales in 1970 Constant Dollars.	74

LIST OF FIGURES

<i>Figure No.</i>	<i>Page</i>
1. The Drug Development Process and the Patent Process	13
2. Annual Approvals of New Chemical Entities Reflecting FDA's Judgment of Therapeutic Potential.	26
A-1. Pesticide R&D Expenditures, Domestic Manufacturers Reporting to NACA, 1967-78	73